Other treatments that impact on different immunomodulatory mechanisms, to induce an immune response against the tumor, have emerged in the last years: anti-PD-1 and anti-CTLA4 [52, 53], BRAF and MEK inhibitors [54–56], and others. The gene discussed is CTLA4; the disease is neoplasm.